|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.62 SEK | +5.22% |
|
+5.81% | +16.87% |
| 18/04 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
| 18/04 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Hansa Biopharma AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 55.98 million compared to SEK 24.19 million a year ago. Net loss was SEK 218.58 million compared to SEK 205.42 million a year ago.
Basic loss per share from continuing operations was SEK 4.15 compared to SEK 3.92 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +16.87% | 177M | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
HANSA BIOPHARMA AB 